Aerie shares shoot up as investigators take another big step to an NDA with 2nd positive glaucoma PhIII
Aerie Pharmaceuticals is now two for two on its pivotal Phase III studies for Roclatan, a combo drug that combines the generic latanoprost to its in-house drug Rhopressa.
Investigators reported top line data today, saying that the combo beat each of the two drugs separately in lowering intraocular pressure, the key gauge for success here.
Once again, Aerie shares $AERI took off on the news, spiking more than 30% Thursday as investors pondered the implications. The biotech promised to file for an approval in the first half of 2018, provided an ongoing safety study ends successfully.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.